AZN.UK

11,278

-0.83%↓

GSK

1,475

+0.61%↑

HLN.UK

341.4

-0.44%↓

STJ

1,252.5

+0.32%↑

HIK

1,633

+0.74%↑

AZN.UK

11,278

-0.83%↓

GSK

1,475

+0.61%↑

HLN.UK

341.4

-0.44%↓

STJ

1,252.5

+0.32%↑

HIK

1,633

+0.74%↑

AZN.UK

11,278

-0.83%↓

GSK

1,475

+0.61%↑

HLN.UK

341.4

-0.44%↓

STJ

1,252.5

+0.32%↑

HIK

1,633

+0.74%↑

AZN.UK

11,278

-0.83%↓

GSK

1,475

+0.61%↑

HLN.UK

341.4

-0.44%↓

STJ

1,252.5

+0.32%↑

HIK

1,633

+0.74%↑

AZN.UK

11,278

-0.83%↓

GSK

1,475

+0.61%↑

HLN.UK

341.4

-0.44%↓

STJ

1,252.5

+0.32%↑

HIK

1,633

+0.74%↑

Search

Oxford Biomedica PLC

Ouvert

574 -2.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

565

Max

593

Chiffres clés

By Trading Economics

Revenu

-11M

Ventes

78M

BPA

-0.11

Marge bénéficiaire

-13.726

Employés

850

EBITDA

5M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+6.6% upside

Dividendes

By Dow Jones

Prochains Résultats

23 sept. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

740M

Ouverture précédente

576.21

Clôture précédente

574

Oxford Biomedica PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2025, 23:01 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Résultats

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Résultats

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Acquisitions, Fusions, Rachats

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Acquisitions, Fusions, Rachats

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Résultats

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Résultats

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Résultats

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparaison

Variation de prix

Oxford Biomedica PLC prévision

Objectif de Prix

By TipRanks

6.6% hausse

Prévisions sur 12 Mois

Moyen 617.207 GBX  6.6%

Haut 930 GBX

Bas 400 GBX

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat